Detalhe da pesquisa
1.
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.
Pharmacogenomics J
; 18(3): 444-449, 2018 05 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29205204
2.
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Leukemia
; 20(10): 1723-30, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16932345
3.
Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine.
Leukemia
; 36(10): 2548-2550, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35963940
4.
Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto.
J Clin Oncol
; 19(20): 4023-8, 2001 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11600603
5.
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Leukemia
; 10(5): 766-8, 1996 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-8656669
6.
Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.
Leukemia
; 7 Suppl 1: 36-41, 1993 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-7683355
7.
Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia.
Leukemia
; 7(4): 549-52, 1993 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-8464233
8.
The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial.
Leukemia
; 17(1): 60-7, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12529661
9.
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.
Leukemia
; 17(6): 1085-90, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12764372
10.
Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Leukemia
; 10(9): 1443-52, 1996 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-8751460
11.
Acute megakaryoblastic leukemia: experience of GIMEMA trials.
Leukemia
; 16(9): 1622-6, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12200673
12.
High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.
Bone Marrow Transplant
; 50(3): 341-7, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25402418
13.
Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes?
Leuk Res
; 19(3): 213-7, 1995 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-7700082
14.
Safety and efficacy of bronchovascular reconstruction after induction chemotherapy for lung cancer.
J Thorac Cardiovasc Surg
; 114(5): 830-5; discussion 835-7, 1997 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-9375614
15.
Multimodality treatment of thymoma: a prospective study.
Ann Thorac Surg
; 64(6): 1585-91; discussion 1591-2, 1997 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-9436540
16.
Bisantrene in relapsed and refractory acute myelogenous leukemia.
Leuk Lymphoma
; 9(3): 217-20, 1993 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-8471980
17.
Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?
Leuk Lymphoma
; 9(1-2): 79-83, 1993 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-8477205
18.
Reversal of encephalopathy during treatment with amphotericin-B.
J Neurol Sci
; 144(1-2): 212-3, 1996 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-8994126
19.
Is workflow technology suitable to represent and manage clinical trials?
Stud Health Technol Inform
; 77: 302-6, 2000.
Artigo
em Inglês
| MEDLINE | ID: mdl-11187562
20.
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.
J Thromb Haemost
; 12(8): 1266-73, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24942752